Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
November 16 2022 - 8:00AM
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company
offering and researching life-saving medicines in a variety of
therapeutic areas, including oncology and antivirals today
announced that it has entered into a collaboration agreement with
one of North America’s leading lipid nanoparticle (“LNP”)
companies. The purpose of the collaboration is to advance the
development of Sunshine Biopharma’s mRNA-based anticancer
macromolecule, K1.1.
The Company’s collaboration partner will prepare
two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s
in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma
had previously shown that its K1.1 mRNA is capable of destroying
cancer cells in vitro, including multidrug resistant breast cancer
cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and
pancreatic cancer cells (SUIT-2). Parallel studies using normal
human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic
effects.
The partner generated K1.1a::LNP and K1.1b::LNP
will be used to conduct in vivo studies on xenograft mice
expressing the in vitro tested human cancers as well as liver
cancer. Should these mice studies prove successful, the Company can
advance relatively rapidly to conducting human trials. The LNP
formulated K1.1 mRNA can be readily adapted for delivery into
patients using the recently gained knowledge from the mRNA vaccine
technology.
“We are delighted to be working with our new
partner and their fully integrated team of experts in LNP
technology,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
About Sunshine Biopharma
Inc.
Sunshine Biopharma recently acquired Nora Pharma
Inc. and as a result the Company now has 36 employees and 50
generic prescription drugs on the market in Canada. In parallel,
Sunshine Biopharma is continuing its drug development R&D
program. In addition to the K1.1 anticancer mRNA project, the
Company is working on the development Adva-27a, a small molecule
having the unique ability to destroy multidrug resistant cancer
cells, including pancreatic cancer cells, small-cell lung cancer
cells, breast cancer cells, and uterine sarcoma cells. Clinical
trials for pancreatic cancer indication are planned to be conducted
at McGill University’s Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma is also engaged in the development of a COVID-19
treatment in collaboration with the University of Arizona. The
project, currently in advanced stages of preclinical studies, is
focused on the development of an inhibitors for SARS-CoV-2 PLpro
protease. PLpro is unique to the SARS group of Coronaviruses and is
responsible for suppressing the human immune system making this
group of viruses more deadly.
Safe Harbor Forward-Looking
Statements
This press release contains forward-looking
statements which are based on current expectations, forecasts, and
assumptions of Sunshine Biopharma, Inc. (the “Company”) that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of the Company, including statements related to the
Company’s drug development activities, financial performance, and
future growth. These risks and uncertainties are further described
in filings and reports by the Company with the U.S. Securities and
Exchange Commission (SEC). Actual results and the timing of certain
events could differ materially from those projected in or
contemplated by the forward-looking statements due to a number of
factors detailed from time to time in the Company’s filings with
the SEC. Reference is hereby made to cautionary statements and risk
factors set forth in the Company’s most recent SEC filings.
For Additional Information:
Sunshine Biopharma Contact:Camille Sebaaly,
CFODirect Line:
514-814-0464camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma Media Contact:Christine
PetragliaTraDigital IRDirect Line:
917-633-8980investors@sunshinebiopharma.com
Sunshine Biopharma (NASDAQ:SBFMW)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunshine Biopharma (NASDAQ:SBFMW)
Historical Stock Chart
From Aug 2023 to Aug 2024